Rutz Michael P

SEC source: 0001193125-26-344757 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,279

F1 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $18.75 - $18.9050. The reporting person hereby undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

SEC source: 0001193125-26-092194 · ownership.xml · derivative · entry 7

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,612

Underlying: Common Stock · 22,612 shares

Expires not disclosed

F7 · derivative.exercise_price: These securities consist of the maximum number of additional performance-based RSUs that were granted on March 2, 2026, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related conditions. The additional RSUs generally vest annually in 60%, 20% and 20% installments, respectfully, commencing March 2027, subject to performance.

F7 · shares: These securities consist of the maximum number of additional performance-based RSUs that were granted on March 2, 2026, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related conditions. The additional RSUs generally vest annually in 60%, 20% and 20% installments, respectfully, commencing March 2027, subject to performance.

F7 · derivative.exercise_date: These securities consist of the maximum number of additional performance-based RSUs that were granted on March 2, 2026, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related conditions. The additional RSUs generally vest annually in 60%, 20% and 20% installments, respectfully, commencing March 2027, subject to performance.

F7 · derivative.expiration_date: These securities consist of the maximum number of additional performance-based RSUs that were granted on March 2, 2026, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related conditions. The additional RSUs generally vest annually in 60%, 20% and 20% installments, respectfully, commencing March 2027, subject to performance.

SEC source: 0001193125-26-092194 · ownership.xml · derivative · entry 6

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,716

Underlying: Common Stock · 14,573 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

F6 · price: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

F6 · derivative.exercise_date: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

F6 · derivative.expiration_date: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

SEC source: 0001193125-26-092194 · ownership.xml · nonDerivative · entry 5

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 484,279

F5 · shares: These securities consist of RSUs that were granted on March 2, 2026, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 2027.

SEC source: 0001193125-26-092194 · ownership.xml · nonDerivative · entry 4

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 439,056

F4 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 43,720 RSUs granted to the Reporting Person on March 3, 2025. This award was granted pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to recieve one share of Common Stock, subject to vesting conditions or performance, as applicable.

SEC source: 0001193125-26-092194 · ownership.xml · nonDerivative · entry 3

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: A portion of the Reporting Person's March 3, 2025 additional performance-based RSUs vested on March 2, 2026 based upon the achievement of performance conditions. As a result, the Reporting Person received an additional 14,573 shares of Common Stock.

F6 · shares: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

F6 · price: These securities consist of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU Agreement under the 2020 Incentive Plan. Each additional RSU represented the Reporting Person's right to receive one share of Common Stock subject to stock price-related performance conditions. Regarding the additional RSUs, the Reporting Person vested in 14,573 shares of Common Stock on March 2, 2026. The remaining additional RSUs under the award vest annually in equal installments in March 2027 and March 2028, subject to performance.

SEC source: 0001193125-26-092194 · ownership.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 441,980

F2 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 11,423 RSUs granted to the Reporting Person on March 4, 2024. This award was granted pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0001193125-26-092194 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 446,475

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 9,475 Restricted Stock Units ("RSUs") granted to the Reporting Person on March 6, 2023. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0001599220-25-000003 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450,204

F1 · price: Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $16.30 - $16.54. The reporting person hereby undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2 · balance_after: These securities consist of 80,901 RSUs and 369,303 shares of Common Stock.

SEC source: 0000950170-25-032831 · ownership.xml · derivative · entry 5

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,289

Underlying: Common Stock · 24,289 shares

Expires not disclosed

F6 · derivative.exercise_price: These securities consist of a maximum number of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related performance conditions. The additional RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026, subject to performance.

F6 · shares: These securities consist of a maximum number of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related performance conditions. The additional RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026, subject to performance.

F6 · derivative.exercise_date: These securities consist of a maximum number of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related performance conditions. The additional RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026, subject to performance.

F6 · derivative.expiration_date: These securities consist of a maximum number of additional performance-based RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each additional RSU represents the Reporting Person's right to receive one share of Common Stock, subject to stock price-related performance conditions. The additional RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026, subject to performance.

SEC source: 0000950170-25-032831 · ownership.xml · nonDerivative · entry 4

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 576,815

F4 · shares: These securities consist of RSUs that were granted on March 3, 2025, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs generally vest annually in 60%, 20%, and 20% installments, respectively, commencing March 3, 2026.

F5 · balance_after: These securities consist of 80,901 RSUs and 495,914 shares of Common Stock. 472,715 of the shares of Common Stock are vested, and 22,199 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0000950170-25-032831 · ownership.xml · nonDerivative · entry 3

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 528,236

F3 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 11,423 RSUs, which represents 33% of the RSU award granted to the Reporting Person on March 4, 2024. This award was granted pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0000950170-25-032831 · ownership.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 533,635

F2 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 9,475 RSUs, which represents 33% of the RSU award granted to the Reporting Person on March 6, 2023. This award was granted pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0000950170-25-032831 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 537,833

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 8,322 Restricted Stock Units ("RSUs"), which represents 33% of the RSU award granted to the Reporting Person on March 2, 2022. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0000950170-24-130298 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 541,520

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 6,521 Restricted Stock Units ("RSUs"), which represents 25% of the RSU award granted to the Reporting Person on November 20, 2020. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

F2 · balance_after: These securities consist of 61,542 RSUs and 479,978 shares of Common Stock. 425,115 of the shares of Common Stock are vested, and 54,863 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0000950170-24-026450 · ownership.xml · derivative · entry 5

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,063

Underlying: Common Stock · 68,063 shares

Expires 2034-03-04

F7 · derivative.exercise_date: These options were granted on March 4, 2024, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest annually in three equal installments commencing March 2, 2025, subject to vesting conditions.

SEC source: 0000950170-24-026450 · ownership.xml · nonDerivative · entry 4

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 544,409

F4 · shares: On March 4, 2024, the Reporting Person sold a total of 83,109 shares of Common Stock of the Issuer in an underwritten public secondary offering (the "Offering").

F5 · price: Reflects a price equal to the Offering price per share less underwriting discounts and commissions payable thereon, as disclosed in the Issuer's Prospectus 424(b)(7), filed with the United States Securities and Exchange Commission on February 29, 2024.

F6 · balance_after: These securities consist of 68,063 RSUs and 476,346 shares of Common Stock. 339,030 of the shares of Common Stock are vested, and 137,316 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0000950170-24-026450 · ownership.xml · nonDerivative · entry 3

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 627,518

F3 · shares: These securities consist of RSUs that were granted on March 4, 2024, pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs vest annually in three equal installments commencing March 2, 2025.

SEC source: 0000950170-24-026450 · ownership.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 593,248

F2 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 9,475 RSUs, which represents 33% of the RSU award granted to the Reporting Person on March 6, 2023. This award was granted pursuant to the terms of an RSU agreement under the 2020 Incentive Plan. Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0000950170-24-026450 · ownership.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 596,311

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 8,320 Restricted Stock Units ("RSUs"), which represents 33% of the RSU award granted to the Reporting Person on March 2, 2022. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

SEC source: 0001822479-23-000071 · wk-form4_1700687335.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 598,749

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 6,522 Restricted Stock Units ("RSUs"), which represents 25% of the RSU award granted to the Reporting Person on November 20, 2020. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

F2 · price: Represents the closing price of the Company's Common Stock on November 20, 2023.

F3 · balance_after: These securities consist of 51,588 RSUs and 547,161 shares of Common Stock. 376,230 of the shares of Common Stock are vested, and 170,931 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-23-000023 · wf-form4_167831510631450.xml · derivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,879

Underlying: Common Stock · 53,879 shares

Expires 2033-03-06

F3 · derivative.exercise_date: These options were granted on March 6, 2023, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest annually in three equal installments commencing March 2, 2024, subject to the Reporting Person's continued service through each such date.

SEC source: 0001822479-23-000023 · wf-form4_167831510631450.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 600,660

F1 · shares: These securities consist of Restricted Stock Units ("RSUs") that were granted on March 6, 2023, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs vest annually in three equal installments commencing March 2, 2024, subject to the Reporting Person's continued service through each such date.

F2 · balance_after: These securities consist of 58,110 RSUs and 542,550 shares of Common Stock. 289,482 of the shares of Common Stock are vested, and 253,068 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-23-000019 · wf-form4_167814657784926.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 572,235

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 8,320 Restricted Stock Units ("RSUs"), which represents 33% of the RSU award granted to the Reporting Person on March 2, 2022. This award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

F2 · price: Represents the closing price of the Company's Common Stock on March 2, 2023.

F3 · balance_after: These securities consist of 29,685 RSUs and 542,550 shares of Common Stock. 273,621 of the shares of Common Stock are vested, and 254,336 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-22-000082 · wf-form4_166915455192982.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 575,183

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 6,521 Restricted Stock Units ("RSUs"), which represents 25% of the RSU award granted to the Reporting Person on November 20, 2020. This RSU award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

F2 · price: Represents the closing price of the Company's Common Stock on November 18, 2022.

F3 · balance_after: These securities consist of 38,005 RSUs and 537,178 shares of Common Stock. 250,495 of the shares of Common Stock are vested, and 286,683 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-22-000021 · wf-form4_164642841992993.xml · derivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,857

Underlying: Common Stock · 63,857 shares

Expires 2032-03-02

F3 · derivative.exercise_date: These options were granted on March 2, 2022, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.

F3 · balance_after: These options were granted on March 2, 2022, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.

SEC source: 0001822479-22-000021 · wf-form4_164642841992993.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 577,094

F1 · shares: These securities consist of Restricted Stock Units ("RSUs") that were granted on March 2, 2022, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of common stock, subject to vesting conditions. The RSUs vest in three equal installments on each of the first three anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.

F2 · balance_after: These securities consist of 44,526 RSUs and 532,568 shares of Common Stock. 162,480 of the shares of Common Stock are vested, and 370,088 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-21-000075 · wf-form4_163771557509209.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 552,132

F1 · shares: These securities represent the number of shares of Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations due upon the vesting of 6,522 Restricted Stock Units ("RSUs"), which represents 25% of the RSU award granted to the Reporting Person on November 20, 2020. This RSU award was granted pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions.

F2 · balance_after: These securities consist of 19,564 RSUs and 532,568 shares of Common Stock. 128,231 of the shares of Common Stock are vested, and 404,337 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0001822479-21-000059 · wf-form4_163010123906263.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 554,043

F1 · price: Represents the weighted-average share price. The lowest price at which shares were sold was $24.90 and the highest price at which shares were sold was $25.39. The Reporting Person undertakes to provide, upon request of the SEC or a security holder of the issuer, complete information regarding the number of shares sold at each price.

F2 · balance_after: Consists of 26,086 Restricted Stock Units ("RSUs") and 527,957 shares of Common Stock. The RSUs were granted on November 20, 2020, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of Common Stock, subject to vesting conditions. The RSUs vest in four equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date. 98,566 of the shares of Common Stock are vested, and 429,391 shares of Common Stock remain subject to vesting conditions. Shares of unvested Common Stock will vest on a daily basis, pro rata through May 13, 2025 (the five year anniversary of the date of grant).

SEC source: 0000899243-20-032067 · doc4.xml · derivative · entry 2

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,801

Underlying: Common Stock · 111,801 shares

Expires 2030-11-20

F3 · derivative.exercise_date: These options were granted on November 20, 2020, pursuant to the terms of a stock option agreement under the 2020 Incentive Plan. The options vest in four equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.

SEC source: 0000899243-20-032067 · doc4.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · President of Sterigenics

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 621,043

F1 · shares: These securities consist of Restricted Stock Units ("RSUs") that were granted on November 20, 2020, pursuant to the terms of an RSU agreement under the Sotera Health Company 2020 Omnibus Incentive Plan ("2020 Incentive Plan"). Each RSU represents the Reporting Person's right to receive one share of common stock, subject to vesting conditions. The RSUs vest in four equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service through each such date.

F2 · balance_after: Consists of 26,086 RSUs and 594,957 shares of Common Stock. 16,199 of the shares of Common Stock are vested, and 578,758 of the shares of Common Stock remain subject to vesting conditions. 20% of the shares of Common Stock will vest on May 13, 2021 (the one year anniversary of the date of grant), and the remaining shares will vest on a daily basis, pro rata through May 13, 2025. See Footnote #1 for information regarding the vesting of the RSUs.

SEC source: 0001567619-20-009265 · doc1.xml · derivative · entry 6

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 732 shares

Expires 2022-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option for 8,140 shares vested in increments of one third annually beginning on the first anniversary of the April 24, 2015 date of grant.

SEC source: 0001567619-20-009265 · doc1.xml · nonDerivative · entry 4

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,324

F2 · price: The shares were sold in multiple transactions at prices ranging from $143.38 to $144.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001567619-20-009265 · doc1.xml · nonDerivative · entry 3

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-009265 · doc1.xml · derivative · entry 5

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 732

Underlying: Common Stock · 7,408 shares

Expires 2022-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option for 8,140 shares vested in increments of one third annually beginning on the first anniversary of the April 24, 2015 date of grant.

SEC source: 0001567619-20-009265 · doc1.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,324

SEC source: 0001567619-20-009265 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-008964 · doc1.xml · derivative · entry 3

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,632 shares

Expires 2023-04-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option for 7,632 shares vested in increments of one third annually beginning on the first anniversary of the April 22, 2016 date of grant.

SEC source: 0001567619-20-008964 · doc1.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,324

F1 · price: The shares were sold in multiple transactions at prices ranging from $144.00 to $144.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0001567619-20-008964 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-20-008706 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,324

F1 · price: Closing price per share on date of vesting of restricted stock units.

SEC source: 0001567619-20-008705 · doc1.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,494

F2 · price: Closing price per share on date of vesting of restricted stock units.

SEC source: 0001567619-20-008560 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,111

F1 · price: Closing price per share on the preceding trading date of the vesting of restricted stock units.

SEC source: 0001567619-20-008705 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,660

F1 · price: Closing price per share on the preceding trading date of the vesting of restricted stock units.

SEC source: 0001567619-19-023110 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,837

SEC source: 0001567619-19-022346 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP & GM Semiconductor Product

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,246

SEC source: 0001567619-19-020876 · doc1.xml · nonDerivative · entry 1

Rutz Michael P · CIK 0001599220 · SVP &GM Semiconductor Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,446

SEC source: 0001567619-19-009441 · doc1.xml · nonDerivative · entry 3

Rutz Michael P · CIK 0001599220 · SVP, GM Semiconductor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,646

F2 · price: Closing price per share on the preceding trading date of the vesting of restricted stock units.

SEC source: 0001567619-19-009441 · doc1.xml · nonDerivative · entry 2

Rutz Michael P · CIK 0001599220 · SVP, GM Semiconductor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,816

F2 · price: Closing price per share on the preceding trading date of the vesting of restricted stock units.

SEC source: 0001567619-19-009441 · doc1.xml · derivative · entry 4

Rutz Michael P · CIK 0001599220 · SVP, GM Semiconductor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,226

Underlying: Common Stock · 6,226 shares

Expires 2026-04-26

F3 · derivative.exercise_date: The option vests in increments of one third annually beginning on the first anniversary of the date of grant.